Dimensional Fund Advisors LP Grows Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Dimensional Fund Advisors LP increased its stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 13.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,480,926 shares of the company's stock after purchasing an additional 176,114 shares during the quarter. Dimensional Fund Advisors LP owned 2.38% of Fulcrum Therapeutics worth $9,182,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. National Bank of Canada FI boosted its position in shares of Fulcrum Therapeutics by 869.6% during the second quarter. National Bank of Canada FI now owns 4,460 shares of the company's stock valued at $28,000 after buying an additional 4,000 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Fulcrum Therapeutics by 66.7% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,916 shares of the company's stock worth $112,000 after acquiring an additional 4,766 shares during the last quarter. SG Americas Securities LLC purchased a new position in Fulcrum Therapeutics during the 1st quarter valued at $115,000. Los Angeles Capital Management LLC bought a new position in Fulcrum Therapeutics in the 2nd quarter valued at $130,000. Finally, Quest Partners LLC purchased a new stake in Fulcrum Therapeutics in the second quarter worth $162,000. Hedge funds and other institutional investors own 89.83% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on FULC shares. Stifel Nicolaus lowered shares of Fulcrum Therapeutics from a "buy" rating to a "hold" rating and lowered their target price for the company from $22.00 to $3.00 in a research note on Thursday, September 12th. HC Wainwright cut shares of Fulcrum Therapeutics from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $17.00 to $4.00 in a research report on Friday, September 13th. Royal Bank of Canada lowered shares of Fulcrum Therapeutics from an "outperform" rating to a "sector perform" rating and reduced their target price for the stock from $15.00 to $4.00 in a research report on Thursday, September 12th. Cantor Fitzgerald lowered Fulcrum Therapeutics from an "overweight" rating to a "neutral" rating in a report on Thursday, September 12th. Finally, Leerink Partnrs cut Fulcrum Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, September 12th. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $9.33.

Fulcrum Therapeutics Stock Performance

NASDAQ:FULC traded down $0.03 during trading hours on Tuesday, reaching $3.54. The company's stock had a trading volume of 627,595 shares, compared to its average volume of 1,031,077. The company has a market capitalization of $220.03 million, a P/E ratio of -2.23 and a beta of 2.21. The stock has a 50 day moving average price of $6.96 and a two-hundred day moving average price of $7.43. Fulcrum Therapeutics, Inc. has a 12 month low of $2.87 and a 12 month high of $13.70.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.87 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.93. Fulcrum Therapeutics had a negative return on equity of 8.28% and a negative net margin of 3,470.05%. The firm had revenue of $80.00 million during the quarter, compared to analyst estimates of $80.00 million. During the same period in the previous year, the company posted ($0.38) EPS. As a group, analysts predict that Fulcrum Therapeutics, Inc. will post -0.28 EPS for the current fiscal year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.